Nutriband Partners with Brand Institute to Develop Global Identity for Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB) has announced a strategic partnership with Brand Institute, Inc. to develop the global commercial brand name and visual identity for AVERSA FENTANYL, the company's lead product utilizing its proprietary AVERSA abuse-deterrent transdermal technology. This collaboration represents a significant step toward bringing what could become the world's first abuse-deterrent opioid patch to market.

The partnership with Brand Institute, which holds a remarkable 75% share of global drug name approvals and 87% of FDA-approved names in 2024, brings substantial regulatory expertise to the project. Brand Institute will work alongside its regulatory subsidiary, Drug Safety Institute, which is staffed by former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO. This regulatory experience is crucial for navigating the complex approval processes required for pharmaceutical products with abuse-deterrent properties.

AVERSA FENTANYL is designed specifically to address two critical issues in opioid therapy: misuse deterrence and reduction of accidental exposure. The AVERSA technology, developed by Nutriband's subsidiary 4P Therapeutics, can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology represents a significant advancement in pain management safety, particularly important given the ongoing opioid crisis that has affected communities worldwide.

The development of an abuse-deterrent fentanyl patch comes at a critical time when healthcare providers and regulators are seeking safer alternatives for managing severe pain. Traditional transdermal fentanyl patches have been subject to abuse through methods such as extraction of the active ingredient or accidental exposure through damaged patches. The AVERSA technology aims to mitigate these risks through its innovative design, which could potentially transform how opioids are administered for chronic pain management.

For investors and industry observers, the partnership signals Nutriband's commitment to advancing its lead product through the crucial commercialization phase. The company's focus on developing a portfolio of transdermal pharmaceutical products positions it at the intersection of pharmaceutical innovation and public health needs. Additional information about the company is available at https://www.nutriband.com, while updates relating to NTRB can be found in the company's newsroom at https://ibn.fm/NTRB.

The broader implications of this development extend beyond the pharmaceutical industry to public health policy and patient safety. If successful, AVERSA FENTANYL could set a new standard for opioid delivery systems, potentially influencing regulatory approaches to abuse-deterrent technologies and providing healthcare providers with a safer option for patients requiring potent pain management solutions. The timing of this development aligns with increased regulatory focus on opioid safety and the medical community's ongoing efforts to balance effective pain treatment with abuse prevention measures.